Sai Parenterals Limited Concludes Financial Year 2025-26, Approves Audited Results
Sai Parenterals Limited announced the outcomes of its Board meeting held on May 23, 2026. The board reviewed and approved the company's financial results, covering the period and quarter ending December 31, 2025, as well as the audited financial results for the year ended March 31, 2026.The company's operational updates highlighted a significant strategic move, detailing the acquisition of a majority and controlling stake in Noumed Life Sciences Limited (UK) through its wholly owned subsidiary, Sai Parenterals Pte Limited (SPPL).
Financial Results for March 31, 2026
The Board approved the audited financial results for the quarter and full year ending March 31, 2026, alongside the corresponding reports from the statutory auditors, noting an unmodified opinion for the year.Standalone Financial Results
The audited standalone financial results for the year ending March 31, 2026, showed substantial growth compared to the previous year. The financials are presented in Millions (₹).| Particulars | 31.03.2026 (Audited) | 31.03.2025 (Audited) |
|---|---|---|
| Total Revenue from Operations | 1979.28 | 961.52 |
| Total Income | 2008.09 | 992.82 |
| Total Expenses | 1884.15 | 587.42 |
| Profit Before Tax | 12394 | 11625 |
| Total Comprehensive Income | 131.83 | (6653) |
| Total Assets | 8,039.79 | 2,149.66 |
| Total Equity | 4369.84 | 912.21 |
Consolidated Financial Results
The consolidated results reflected the overall performance of the group. Key figures are detailed below (in Millions).| Particulars | 31.03.2026 (Audited) | 31.03.2025 (Audited) |
|---|---|---|
| Total Revenue from Operations | 1979.28 | 961.52 |
| Total Income | 2008.09 | 992.82 |
| Total Expenses | 1884.15 | 587.42 |
| Profit Before Tax | 12394 | 11625 |
| Total Comprehensive Income | 131.83 | (6653) |
| Total Assets | 14242.29 | 2723.91 |
| Total Equity | 4951.26 | 957.79 |
Cash Flow Highlights
The company’s cash generation remains robust, as detailed in the audited consolidated cash flow statement for the year ended March 31, 2026.| Activity | 31.03.2026 (Audited) | 31.03.2025 (Audited) |
|---|---|---|
| Cash from Operating Activities (A) | 13554.7 | 1160 |
| Cash from Investing Activities (B) | 44.71 | 906.57 |
| Cash from Financing Activities (C) | 1445 | 113,249.43 |
| Net Cash Inflow / (Outflow) (A+B+C) | 1445 | 2298 |
Strategic Acquisitions and Investments
Regarding corporate development, Sai Parenterals made final payments through its wholly owned subsidiary, Sai Parenterals Pte Limited (SPPL), to Noumed Life Sciences Limited (UK) ('NLS'). This payment facilitated the acquisition of a majority and controlling stake of 74.64% for an aggregate consideration of AUD 22.00 million, which included a primary infusion of AUD 4.00 million.Furthermore, the company invested into SPPL by way of equity for an aggregate amount of 1,066.13 million, subsequent to September 30, 2025, to complete the acquisition.
Subsidiary Overview
The group's operations encompass both domestic and international markets, focusing on branded generic formulations and Contract Development and Manufacturing Organisation (CDMO) products and services.The company has five subsidiaries, including two step-down subsidiaries:
| Category | Company Name | Total Revenue (Rs. In Millions) | Total Profit/(Loss) (Rs. In Millions) |
|---|---|---|---|
| Indian Subsidiary | Revat Laboratories Private Limited | 598.28 | 42.11 |
| Indian Subsidiary | SP Analytics Private Limited | 0 | -2.91 |
| Foreign Subsidiary | Sai Parenterals Pte. Limited | 21.92 | 5.04 |
| Foreign Step-down Subsidiary | Noumed Pharmaceuticals Pty Limited | 1682.49 | -85.52 |
| Foreign Step-down Subsidiary | Noumed Pharmaceuticals Limited | 156.37 | 16.11 |
SAIPARENT Stock Price Movement
On Friday, Sai Parenterals Limited shares edged higher to close at ₹486.7, gaining 2.06% for the session. The stock traded on a robust volume of 170,762 shares, finding support within a daily range of ₹479.55 to ₹493.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.